The tumour selectivity and safety of soluble recombinant TRAIL in vivo have been examined in various studies, and it was generally found to be well tolerated even when multiple doses were administered to animals (Ashkenazi et al, 1999; Walczak et al, 1999; Fulda et al, 2002). This evidence concerns the gene TNFSF10 and neoplasm.